How to prevent relapse after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia and myelodysplastic syndrome
(2017) Current Research in Translational Medicine — Vol. 65, n° 2, p. 65-69 (2017)
Files
1-s20-S245231861730017X-main.pdf
Open Access - Adobe PDF
- 375.46 KB
Details
- Authors
- Abstract
- Disease relapse remains the first cause of mortality of hematological malignancies after allogeneic hematopoietic stem cell transplantation (allo-HCT). The risk of recurrence is elevated in acute myeloid leukemia (AML) patients with high-risk cytogenetic or molecular abnormalities, as well as when allo-HCT is performed in patients with refractory hematological malignancies or with persistent molecular or radiological (PET-CT scan) residual disease. For high risk AML and myelodysplasia (MDS), a post transplant maintenance strategy is possible, using hypomethylating agents or tyrosine kinase inhibitors (TKI) anti-FLT3 when the target is present. For Philadelphia positive acute lymphoblastic leukemia (ALL), there is a consensus for the use of TKI anti BCR-ABL as post transplant maintenance.
- Affiliations
Citations
Yafour, N., Beckerich, F., Bulabois, C. E., Chevallier, P., Daguindau, E., Dumesnil, C., Guillaume, T., Huynh, A., Masouridi Levrat, S., Menard, A. L., Pautas, C., Poiré, X., Ravinet, A., Michallet, M., & Bazarbachi, A. (2017). How to prevent relapse after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia and myelodysplastic syndrome. Current Research in Translational Medicine, 65(2), 65-69. https://doi.org/10.1016/j.retram.2017.06.001 (Original work published 2017)